G-CSF Antibody Treatment for COPD Neutrophil Infiltration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic obstructive pulmonary disease (COPD) and associated conditions, such as acute exacerbated COPD, are ineffective in addressing the inflammatory response and neutrophil infiltration, leading to progressive airflow limitation and lung function decline.
Innovation Solution
Inhibiting the activity of granulocyte-colony stimulating factor (G-CSF) or its receptor (G-CSFR) using antagonists, including antibodies and nucleic acid molecules, to reduce neutrophil infiltration and associated inflammation in the lungs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory treatments (glucocorticosteroids) are used, then some inflammatory reduction is achieved, but they produce little or no benefit in COPD and cause significant side effects
Solution Approach 1:
The patent extracts and targets a specific pathway (G-CSF signaling) responsible for neutrophil infiltration, separating the therapeutic action from non-specific anti-inflammatory treatments. By using G-CSF receptor antagonists, the treatment specifically blocks the harmful neutrophil-driven inflammation without the broad side effects of glucocorticosteroids.
Solution Approach 2:
The patent changes the mechanism of action from non-specific glucocorticosteroid inhibition to specific G-CSF receptor blocking. This parameter change in the therapeutic approach allows targeted reduction of neutrophil infiltration while avoiding the harmful side effects associated with traditional anti-inflammatory drugs.
2Reliability
If neutrophil infiltration is increased to fight infection, then immune defense is improved, but it causes progressive airflow limitation and lung function decline in COPD
Solution Approach 1:
The patent converts the harmful effect of neutrophil infiltration into a beneficial targeted treatment. By using G-CSF receptor antagonists, the treatment specifically blocks the harmful migration and activation of neutrophils in COPD lungs, transforming the previously harmful inflammatory response into a controlled, targeted intervention that preserves lung function.
3Object-generated harmful factors
If G-CSF activity is inhibited to reduce neutrophil infiltration, then lung inflammation is decreased, but neutrophil production and release from bone marrow may be affected
Solution Approach 1:
The patent applies local quality by using soluble G-CSF receptor antagonists that can be administered systemically but primarily act on G-CSF binding sites in the lung tissue. This localized action reduces neutrophil infiltration in the lung while having minimal impact on bone marrow neutrophil production, as the antagonist preferentially blocks G-CSF at its receptor in the lung microenvironment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively decreases neutrophil numbers and inflammatory mediators in bronchoalveolar fluid and blood, reducing lung inflammation and potentially slowing lung function decline in COPD patients.
Implementation Method 1
administering an antibody to G-CSF
Data Source
AI summary
The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or its receptor, interfere with G-CSF signaling and/or which down-regulate expression of G-CSF or its receptor.